Related Experiment Videos
Expression and mutational analysis of the MADR2/Smad2 gene in human prostate cancer
Background:
Loss of heterozygosity (LOH) on chromosome arm 18q is common in sporadic prostate cancer and may be involved in cancer development through inactivation of tumor-suppressor genes (TSG). Recent identification, at 18q21.1, of MADR2/Smad2, a key component in transforming growth factor beta (TGFbeta)-family signaling pathways, led us to investigate the role of this gene in prostate tumorigenesis.
Methods:
Sporadic primary prostate tumors from 25 patients with clinically localized tumors and 7 with metastatic forms were examined for MADR2/Smad2 mutations by using polymerase chain reaction-single-strand conformational polymorphism (PCR-SSCP) analysis of cDNA, and for gene expression by quantitative reverse transcription-polymerase chain reaction (RT-PCR).
Results:
We detected no mutation in MADR2/Smad2 and no abnormal mRNA expression.
Conclusions:
Despite recent evidence indicating that MADR2/Smad2 acts as a tumor-suppressor gene, our findings suggest a limited role of this gene in prostate tumorigenesis, at least in the early stages. Another key tumor-suppressor gene may therefore be the main target of the observed LOH at 18q21.1.
Insights
Loss of heterozygosity (LOH) on chromosome 18q is common in prostate cancer. Researchers found no mutations or abnormal expression of the MADR2/Smad2 gene, suggesting it plays a limited role in prostate tumor development.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Loss of heterozygosity (LOH) on chromosome 18q is frequent in sporadic prostate cancer.
- This LOH may inactivate tumor-suppressor genes (TSGs).
- MADR2/Smad2, a gene in transforming growth factor beta (TGFbeta) signaling, was identified at 18q21.1.
Purpose of the Study:
- To investigate the role of the MADR2/Smad2 gene in prostate tumorigenesis.
- To determine if MADR2/Smad2 mutations or altered expression are associated with prostate cancer development.
Main Methods:
- Analysis of MADR2/Smad2 mutations using polymerase chain reaction-single-strand conformational polymorphism (PCR-SSCP) on cDNA from 32 primary prostate tumors.
- Quantitative reverse transcription-polymerase chain reaction (RT-PCR) to assess MADR2/Smad2 gene expression.
Main Results:
- No mutations were detected in the MADR2/Smad2 gene across the analyzed prostate tumors.
- No abnormal messenger RNA (mRNA) expression levels of MADR2/Smad2 were observed.
Conclusions:
- MADR2/Smad2 appears to have a limited role in prostate tumorigenesis, particularly in early stages.
- The observed LOH at 18q21.1 in prostate cancer likely targets other tumor-suppressor genes.
- Further research is needed to identify the specific TSGs involved in 18q LOH-mediated prostate cancer development.